Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein

被引:184
作者
Basta, Giuseppina
Sironi, Anna Maria
Lazzerini, Guido
Del Turco, Serena
Buzzigoli, Emma
Casolaro, Arturo
Natali, Andrea
Ferrannini, Ele
Gastaldelli, Amalia
机构
[1] CNR, Inst Clin Physiol, I-56124 Pisa, Italy
[2] Univ Pisa, Sch Med, Dept Internal Med, I-56124 Pisa, Italy
关键词
D O I
10.1210/jc.2005-2559
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The interaction of advanced glycation end products, including N epsilon-( carboxymethyl) lysine- protein adducts ( CML) and S100A12 protein, with their cellular receptor ( RAGE) is implicated in the pathogenesis of diabetic vascular complications. RAGE has a circulating secretory receptor form, soluble RAGE ( sRAGE), which, by neutralizing the action of advanced glycation end products, might exert a protective role against the development of cardiovascular disease. Objective: The objective of the study was to investigate whether plasma sRAGE levels are associated with glycemic control, proinflammatory factors, or circulating ligands of RAGE such as plasma CML and S100A12 protein. Study Design: Westudied 160 subjects, 84 subjects with type 2 diabetes ( aged 60 +/- 7 yr) and 76 nondiabetic controls ( aged 45 +/- 10 yr). Results: Plasma sRAGE was lower in diabetic patients than controls [ 141 ( 53 +/- 345) vs. 735 ( 519 +/- 1001) pg/ ml, median ( interquartile range), P < 0.0001], whereas CML levels were higher in diabetic patients than controls [ 67.9 ( 46.0 +/- 84.7) vs. 43.4 ( 28.0 +/- 65.0) mu g/ ml, P < 0.0001]. In stepwise regression analysis of the whole data set, hemoglobin A1c, insulin resistance ( as homeostasis model assessment), and C- reactive protein were independently associated with plasma sRAGE, whereas age was not. In a subgroup of 26 diabetic and 24 nondiabetic subjects of similar age ( 54 +/- 3 yr), plasma S100A12 levels were higher in diabetic subjects [ 49 ( 39 - 126) vs. 28 ( 21 - 39) ng/ ml]. Moreover, low sRAGE and high S100A12 were strongly associated with increased risk for cardiovascular disease ( Framingham score). In this subgroup, the plasma S100A12 level was the only determinant of plasma sRAGE concentration. Conclusion: Plasma level of sRAGE is down- regulated in chronic hyperglycemia; among its ligands, S100A12 protein, but not CML, appears to be associated with this effect.
引用
收藏
页码:4628 / 4634
页数:7
相关论文
共 38 条
[1]   Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes [J].
Basta, G ;
Schmidt, AM ;
De Caterina, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :582-592
[2]   Diabetes-associated sustained activation of the transcription factor nuclear factor-κB [J].
Bierhaus, A ;
Schiekofer, S ;
Schwaninger, M ;
Andrassy, M ;
Humpert, PM ;
Chen, J ;
Hong, M ;
Luther, T ;
Henle, T ;
Klöting, I ;
Morcos, M ;
Hofmann, M ;
Tritschler, H ;
Weigle, B ;
Kasper, M ;
Smith, M ;
Perry, G ;
Schmidt, AM ;
Stern, DM ;
Häring, HU ;
Schleicher, E ;
Nawroth, PP .
DIABETES, 2001, 50 (12) :2792-2808
[3]   RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice [J].
Bucciarelli, LG ;
Wendt, T ;
Qu, W ;
Lu, Y ;
Lalla, E ;
Rong, LL ;
Goova, MT ;
Moser, B ;
Kislinger, T ;
Lee, DC ;
Kashyap, Y ;
Stern, DM ;
Schmidt, AM .
CIRCULATION, 2002, 106 (22) :2827-2835
[4]  
DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929
[5]   Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men [J].
Falcone, C ;
Emanuele, E ;
D'Angelo, A ;
Buzzi, MP ;
Belvito, C ;
Cuccia, M ;
Geroldi, D .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) :1032-1037
[6]   Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice [J].
Flyvbjerg, A ;
Denner, L ;
Schrijvers, BF ;
Tilton, RG ;
Mogensen, TH ;
Paludan, SR ;
Rasch, R .
DIABETES, 2004, 53 (01) :166-172
[7]   Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis [J].
Foell, D ;
Kane, D ;
Bresnihan, B ;
Vogl, T ;
Nacken, W ;
Sorg, C ;
FitzGerald, O ;
Roth, J .
RHEUMATOLOGY, 2003, 42 (11) :1383-1389
[8]   Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease [J].
Foell, D ;
Kucharzik, T ;
Kraft, M ;
Vogl, T ;
Sorg, C ;
Domschke, W ;
Roth, J .
GUT, 2003, 52 (06) :847-853
[9]   S100A12 (EN-RAGE) in monitoring Kawasaki disease [J].
Foell, D ;
Ichida, F ;
Vogl, T ;
Yu, XY ;
Chen, R ;
Miyawaki, T ;
Sorg, C ;
Roth, J .
LANCET, 2003, 361 (9365) :1270-1272
[10]   Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy [J].
Forbes, JM ;
Thorpe, SR ;
Thallas-Bonke, V ;
Pete, J ;
Thomas, MC ;
Deemer, ER ;
Bassal, S ;
El-Osta, A ;
Long, DM ;
Panagiotopoulos, S ;
Jerums, G ;
Osicka, TM ;
Cooper, ME .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (08) :2363-2372